Susquehanna International Group LLP acquired a new stake in shares of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 718,076 shares of the business services provider’s stock, valued at approximately $646,000. Susquehanna International Group LLP owned approximately 3.84% of Interpace Diagnostics Group as of its most recent SEC filing.

A number of equities research analysts recently weighed in on IDXG shares. Maxim Group started coverage on shares of Interpace Diagnostics Group in a research note on Tuesday, August 15th. They set a “buy” rating and a $5.00 price objective on the stock. ValuEngine upgraded shares of Interpace Diagnostics Group from a “strong sell” rating to a “sell” rating in a research note on Monday, September 11th.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at

Interpace Diagnostics Group, Inc. (IDXG) traded down 5.73% on Friday, reaching $1.48. The company had a trading volume of 1,765,743 shares. The company’s market capitalization is $32.80 million. The company’s 50 day moving average price is $1.50 and its 200-day moving average price is $1.60. Interpace Diagnostics Group, Inc. has a 12 month low of $0.70 and a 12 month high of $19.80.

Interpace Diagnostics Group (NASDAQ:IDXG) last issued its quarterly earnings results on Thursday, August 10th. The business services provider reported ($0.65) earnings per share (EPS) for the quarter. Interpace Diagnostics Group had a negative net margin of 37.08% and a negative return on equity of 32.06%. The firm had revenue of $3.86 million for the quarter.

Interpace Diagnostics Group Profile

Interpace Diagnostics Group, Inc, formerly PDI, Inc, is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management.

Receive News & Ratings for Interpace Diagnostics Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group Inc. and related companies with's FREE daily email newsletter.